GSK Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by GSK Plc, dated November 19, 2024, serves as a transaction notification for the month of November 2024. The report discloses specific share transactions involving Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on insider trading activity.
Material Changes and Transaction Details
The filing reports three separate transactions executed on November 15, 2024, on the New York Stock Exchange (XNYS). All transactions involved the acquisition of American Depositary Shares (ADSs) via dividend reinvestment plans at a price of $33.35 per ADS.
- Dr. Hal Barron (Non-Executive Director): Acquired 3,447.093 ADSs through the GSK Executive Supplemental Savings Plan.
- James Ford (SVP and Group General Counsel): Acquired 64.142 ADSs through the GSK Executive Supplemental Savings Plan.
- Dr. Hal Barron (Non-Executive Director): Acquired 87 ADSs through the GSK 401(k) plan.
Guidance, Outlook, and Risks
The filing text does not provide management commentary, financial guidance, outlook, risk factors, or contingencies. It is a statutory disclosure of insider transactions only.
Key Facts for Investor Verification
- Verify the total volume of ADSs acquired by Dr. Hal Barron across both plans (3,534.093 ADSs).
- Confirm the transaction price of $33.35 aligns with the market price of GSK ADSs on November 15, 2024.
- Note that all reported transactions were automatic acquisitions resulting from dividend reinvestment, not open-market purchases.